Depot and oral antipsychotics: Patient preferences and attitudes are not the same thing

Journal of Psychopharmacology

Volumn 23, Issue 7, 2009, Pages 789-796

  Patel, M X ^a   De Zoysa, N ^a   Bernadt, M ^a   David, A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotic agents; Attitudes; Delayed action preparations; Patients; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FLUPENTIXOL DECANOATE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SULPIRIDE; ZUCLOPENTHIXOL DECANOATE;

ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE DURATION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; INTROSPECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PRIORITY JOURNAL; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TABLET;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; ATTITUDE; CHEMISTRY, PHARMACEUTICAL; CROSS-SECTIONAL STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PSYCHOTIC DISORDERS; QUESTIONNAIRES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 69049107779     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108092124     Document Type: Article

References (33)

1. Adewuya AO. Ola BA. Mosaku SK. Fatoye FO. Eegunranti AB. (2006) Attitudes towards antipsychotics among out-patients with schizophrenia in Nigeria. Acta Psychiatr Scand 113: 207-211.
2. Awad AG. Hogan TP. Voruganti LN. Heslegrave RJ. (1995) Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol 10 (Suppl. 3). 123-132.
3. Birchwood M. Smith J. Drury V. Healy J. MacMillan F. Slade M. (1994) A self-report Insight Scale for psychosis: reliability, validity and sensitivity to change. Acta Psychiatr Scand 89: 62-67.
4. Castle D. Morgan V. Jablensky A. (2002) Antipsychotic use in Australia: the patients' perspective. Aust N Z J Psychiatry 36: 633-641.
5. Davis JM. Matalon L. Watanabe MD. Blake L. (1994) Depot antipsychotic drugs. Place in therapy. Drugs 47: 741-773.
6. Day JC. Bentall RP. Roberts C. Randall F. Rogers A. Cattell D. (2005) A comparison of patients' and prescribers' beliefs about neuroleptic side-effects: prevalence, distress and causation. Arch Gen Psychiatry 62: 717-724.
7. Day JC. Kinderman P. Bentall R. (1998) A comparison of patients' and prescribers' beliefs about neuroleptic side-effects: prevalence, distress and causation. Acta Psychiatr Scand 97: 93-97.
8. Day JC. Wood G. Dewey M. Bentall RP. (1995) A self-rating scale for measuring neuroleptic side-effects: validation in a group of schizophrenic patients. Br J Psychiatry 166: 650-653.
9. Dencker SJ. Axelsson R. (1996) Optimising the use of depot antipsychotics. CNS Drugs 6: 367-381.
10. Freudenreich O. Cather C. Evins AE. Henderson DC. Goff DC. (2004) Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry 65: 1372-1376.
11. Gerlach J. (1995) Depot neuroleptics in relapse prevention: advantages and disadvantages. Int Clin Psychopharmacol 9 (Suppl. 5). 17-20.
12. Gerlach J. Larson EB. (1999) Subjective experience and mental side-effects of antipsychotic treatment. Acta Psychiatr Scand 99 (Suppl. 395). 113-117.
13. Glazer WM. Kane JM. (1992) Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 53: 426-433.
14. Hellewell JSE. (2002) Patients' subjective experiences of antipsychotics-clinical relevance. CNS Drugs 16: 457-471.
15. Hoencamp E. Knetering H. Kooy JJS. Van der Molen AEGM. (1995) Patient requests and attitude towards neuroleptics. Nord J Psychiatry 49 (Suppl. 35). 47-55.
16. Hofer A. Kemmler G. Eder U. Edlinger M. Hummer M. Fleischhacker WW. (2004) Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication and side effects. J Clin Psychiatry 65: 932-939.
17. Hogan TP. Awad AG. (1992) Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 22: 347-352.
18. Hogan TP. Awad AG. Eastwood R. (1983) A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 13: 177-183.
19. Kane JM. Aguglia E. Altamura AC. Ayuso Gutierrez JL. Brunello N. Fleischhacker WW. (1998) Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 8: 55-66.
20. Marder S. (2005) Subjective experiences on antipsychotic medications: synthesis and conclusions. Acta Psychiatr Scand 111 (Suppl. 427). 43-46.
21. McEvoy JP. (2004) The relationship between insight in psychosis and compliance with medications. In: XF Amador. AS David. (eds). Insight and Psychosis, second ed. Oxford: Oxford University Press, pp. 311-334.
22. http://www.statistics.gov.uk/census2001 (ethnicity categorisation). Accessed 1st October 2002.
23. Patel MX. David AS. (2005) Why aren't depots prescribed more often, and what can be done about it. Adv Psychiatr Treat 11: 203-213.
24. Patel MX. De Zoysa N. Baker D. David AS. (2005) Depot antipsychotic medication and attitudes of community psychiatric nurses. J Psychiatr Ment Health Nurs 12: 237-244.
25. Patel MX. Nikolaou V. David AS. (2003) Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol Med 33: 83-89.
26. Pereira S. Pinto R. (1997) A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatr Scand 95: 464-468.
27. Rofail D. Gray R. Gournay K. (2005) The development and internal consistency of the satisfaction with Antipsychotic Medication Scale. Psychol Med 35: 1063-1072.
28. Royal Pharmaceutical Society of Great Britain (2007) British National Formulary version 54. Mehta D. (Ed). London.
29. Svedberg B. Backenroth-Ohsako G. Lutzen K. (2003) On the path to recovery: patients' experiences of treatment with long-acting injections of antipsychotic medication. Int J Mental Health Nursing 12: 110-118.
30. Taylor D. Mir S. Mace S. Hogman G. (1999) Is Cost a Factor - II? A Survey of Psychiatrists and Health Authorities to Determine the Factors Influencing the Prescribing and Funding of Atypical Antipsychotics. London: National Schizophrenia Fellowship.
31. VanPutten T. May PRA. Marder SR. Wittman LA. (1981) Subjective response to antipsychotic drugs. Arch Gen Psychiatry 38: 187-190.
32. Walburn J. Gray R. Gournay K. Quraishi S. David AS. (2001) A systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 179: 300-307.
33. World Health Organisation (1992) The International Classification of Diseases, version 10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines (ICD-10). Geneva: WHO.